Filing Summary
Registrant and period: GX Acquisition Corp. filed this Form 8-K on May 14, 2021. The filing concerns its proposed business combination with Celularity Inc., an allogeneic cellular therapy company; GX intended for Celularity to become a wholly owned subsidiary. This is a transaction update, not an operating or quarterly financial report.
Material Transaction Developments
- On May 12, 2021, GX, its merger subsidiaries, and Celularity entered into a letter agreement extending the merger agreement’s initial outside date to July 31, 2021.
- The extension followed stockholder approval to extend GX’s business-combination deadline from May 23, 2021 to July 31, 2021.
- The filing includes the letter agreement and an amendment to GX’s amended and restated certificate of incorporation as exhibits.
Stockholder Vote and Redemptions
- At least 17,968,751 shares were represented at the special meeting, equal to approximately 71.857% of the voting power as of the March 23, 2021 record date.
- The extension proposal was approved with 25,444,230 votes for, 26,219 against, and 353,252 abstentions.
- An adjournment proposal was approved with 24,765,280 votes for, 706,819 against, and 351,602 abstentions.
- Holders of 16,169,996 Class A shares elected redemption at approximately $10.15 per share.
- Approximately $164.1 million was expected to be withdrawn from GX’s trust account to fund the redemptions.
Financial Metrics, Liquidity, and Outlook
The filing does not provide revenue, profit, operating cash flow, margins, debt, or other operating performance metrics for GX or Celularity. It does disclose the expected $164.1 million reduction in the trust account, which decreases the cash available for the proposed business combination. The filing does not state a revised transaction closing date beyond the July 31, 2021 outside date, nor does it provide financial guidance.
Risks and Unusual Items
- Completion of the Celularity transaction remained subject to the applicable merger agreement conditions and the extended outside date.
- The substantial share redemptions reduced the trust-account proceeds available to the combined company.
- The filing does not quantify any additional financing, revised transaction consideration, or pro forma capitalization following the redemptions.
Key Facts for Investor Verification
- Verify the full Letter Agreement filed as Exhibit 2.1 and the precise conditions and implications of the July 31, 2021 outside-date extension.
- Confirm the final number and value of redeemed shares and the resulting trust-account balance.
- Review the merger agreement, proxy statement, and any subsequent filings for transaction closing conditions, financing requirements, dilution, and pro forma ownership.
- Confirm whether the Celularity transaction ultimately closed and whether further amendments or extensions were filed.